Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "ChemMedChem"
DOI: 10.1002/cmdc.201700781
Abstract: Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose‐dependent insulin secretion. Further, GLP‐1 is also associated with protective effects… read more here.
Keywords: peptide; glucagon like; glp; peptide glp ... See more keywords
Glucagon-like Peptide-1 (GLP-1) Signaling in the Brain: From Neural Circuits and Metabolism to Therapeutics.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of pharmacology"
DOI: 10.1111/bph.15682
Abstract: Glucagon-like-peptide-1 (GLP-1) derived from gut enteroendocrine cells and a discrete population of neurons in the caudal medulla act through humoral and neural pathways to regulate satiety, gastric motility, and pancreatic endocrine function. These physiological attributes… read more here.
Keywords: glucagon like; glp; peptide glp; neural circuits ... See more keywords
The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Endocrinology"
DOI: 10.1111/cen.14583
Abstract: The mainstay management of hyperphagia and obesity in Prader–Willi syndrome (PWS) relies on dietary restrictions, strict supervision and behavioural modifications, which can be stressful for the patient and caregiver. There is no established pharmacological strategy… read more here.
Keywords: peptide glp; prader willi; glucagon like; glp receptor ... See more keywords